Ripretinib
Ripretinib is a pharmaceutical drug with 8 clinical trials. Currently 3 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
1
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
75.0%
3 of 4 finished
25.0%
1 ended early
3
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
Ripretinib (QINLOCK®) According to Current SmPC
A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
Clinical Trials (8)
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
Ripretinib (QINLOCK®) According to Current SmPC
A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST
Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)
Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST
All 8 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 8